Navigation Links
Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
Date:3/24/2009

mitted to continuing to invest in this promising technology and to bring it to market as soon as possible."

The ABSORB trial reinforces Abbott's commitment to research and develop innovative devices in vascular care. Abbott's robust vascular research program includes clinical trials in peripheral artery disease, carotid artery disease, and coronary artery disease. Key products in the vascular pipeline include: the Omnilink Elite(TM) Peripheral Stent System; the EMBOSHIELD NAV6(TM) Embolic Protection System for carotid stenting; and the XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System, which builds upon the proven performance of Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System.

Onmilink Elite, EMBOSHIELD NAV6 and XIENCE PRIME are investigational devices and are not available for sale.

About the ABSORB Clinical Trial

The ABSORB trial is a prospective, non-randomized (open label), two-phase study designed to enroll approximately 110 patients in Australia, Belgium, Denmark, France, the Netherlands, New Zealand, Poland and Switzerland. Key endpoints of the study include assessments of safety - MACE and stent thrombosis rates - at 30 days; six, nine, 12 and 18 months; and two years, with additional annual clinical follow-up for up to five years, as well as an assessment of the acute performance of the bioabsorbable drug eluting stent, including successful deployment of the system. Other key endpoints of the study include imaging assessments by angiography, intravascular ultrasound (IVUS), optical coherence tomography (OCT), and other state-of-the-art invasive and non-invasive imaging modalities at six months, one year and two years.

Abbott's bioabsorbable drug eluting device delivers everolimus, a drug that inhibits tissue proliferation. The device props open and supports a narrowed blood vessel until the vessel heals, restoring blood flow, and is abs
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
2. Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
3. Abbott Receives Complete Response Letter From FDA for Controlled-Release Hydrocodone With Acetaminophen
4. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
5. Continuous Treatment With Abbotts HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
6. Abbotts Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
7. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
8. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
9. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
10. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... August 3, 2015 Global ... to reach USD 24.7 billion by 2022, according ... Inc. Growing prevalence of neurological and musculoskeletal disorders ... over the forecast period. The presence of efficient ... advancement in the technologies coupled with implementation of ...
(Date:8/3/2015)... RADNOR, Pa. , Aug. 3, 2015 ... of laboratory products, services and solutions, announces the redesign of ... its customers. When visiting the new site, ... site with bold colors and vivid images.  Each country site ... , an A to Z product menu; and , ...
(Date:8/3/2015)... 3, 2015  BioElectronics Corporation (OTC Pink: BIEL), maker ... that Andrew J. Whelan , President will be ... "On Business" at 9am EDT on Wednesday, August 5 ... to: http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ ... acceptance the company,s flagship product, ActiPatch Therapy, is achieving ...
Breaking Medicine Technology:Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 3Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 5VWR's New Website Redesign Provides Improved Functionality for Customers 2UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2
... Reportlinker.com announces that a new market research report ... Colorectal Cancer - France Drug Forecasts and Treatment ... Colorectal Cancer - France ... SummaryGlobalData, the industry analysis specialist, has ...
... West Booth# 19112 -- In anticipation of SupplySide West ... that it has entered into a strategic agreement with Mantrose-Haeuser ... distribution of its HIDROX® products, used in dietary supplement and ... "We are looking at the market for dietary supplements and ...
Cached Medicine Technology:Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 2Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 3Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 4Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 5Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 6Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 7Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 8Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 9Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 10Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 11Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 12Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 13Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 14Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 15CREAGRI Partners With Mantrose-Haeuser Co., Inc. for the Distribution of Its HIDROX® 2CREAGRI Partners With Mantrose-Haeuser Co., Inc. for the Distribution of Its HIDROX® 3
(Date:8/3/2015)... Angeles, CA (PRWEB) , ... August 03, 2015 , ... According to an opinion ... calories out of person’s diet leads to one pound of weight loss may not be ... caloric reduction that translates to one pound of fat varies – based both on the ...
(Date:8/3/2015)... Princeton, NJ (PRWEB) , ... August 03, 2015 ... ... named a finalist in 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs ... by and for B2B brands. BESLER Consulting's campaign for the launch of their ...
(Date:8/3/2015)... CA (PRWEB) , ... August 03, 2015 , ... ... Hispanic Health notes that while an overwhelming number of Hispanics believe people ... , The overwhelming 70 percent of participants queried said making diet changes was ...
(Date:8/3/2015)... ... August 03, 2015 , ... Social impact organization’s #HelpOneHelpMany ... 2015 – Since winning a South by Southwest® (SXSW®) Interactive Innovation Award in ... whose mission is to develop technology for the sake of humanity – continues ...
(Date:8/3/2015)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions ... Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker Meridien in New York, ... be accessed via the investor relations section of the Company’s website. , About AxoGen, ...
Breaking Medicine News(10 mins):Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2
... Goal of 40 million doses by end of October won,t ... -- Production delays continue to hamper distribution of the H1N1 ... , The vaccine is growing more slowly in egg-based cultures ... this time, Dr. Thomas R. Frieden, director of the U.S. ...
... heart patients when ARB added to ACE inhibitor therapy, study ... angiotensin receptor blocker (ARB) drug to help control blood pressure ... are taking an ACE inhibitor, a new study finds. , ... therapy seems no better than ACE inhibitor therapy alone and ...
... lower-than-normal levels of a naturally-occurring fat hormone may increase ... the blood which claims thousands of lives each year. ... Hospital and the University of Toronto focused on adiponectin, ... organs. The findings were presented this week at the ...
... new Commonwealth Fund report analyzes the similarities, differences, potential ... five committees of jurisdiction in the United States Congress: ... Committees in the Senate and the U.S. House of ... and Commerce committees. The report, Provisions of Comprehensive ...
... research finds that mother,s drug use affects male offspring,s behavior ... monkeys exposed to cocaine in the womb have poor impulse ... research has found. , The male monkeys continued to have ... risk factor for drug abuse, said the researchers, who added ...
... More than half the people who take antidepressants for depression ... depression has been oversimplified and drugs designed to treat it ... the Northwestern University Feinberg School of Medicine. The medications are ... eye instead of the center. A study from ...
Cached Medicine News:Health News:Swine Flu Vaccine Still in Short Supply 2Health News:Swine Flu Vaccine Still in Short Supply 3Health News:Adding Drug Doesn't Help Control Blood Pressure 2Health News:Canadian scientists link fat hormone to death from potentially deadly blood infection 2Health News:Analysis of Congressional health reform bills highlights similarities, differences, costs 2Health News:Cocaine Use in Pregnancy Linked to Impulsivity in Sons 2Health News:Why antidepressants don't work for so many 2Health News:Why antidepressants don't work for so many 3
Bechert-McPherson tying forceps, angled, 10 mm tying platforms....
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Girard curved tying forceps made of titanium has curved shafts with 8 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 99 mm....
Girard straight tying forceps made of titanium has straight shafts with 6 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 105 mm....
Medicine Products: